Cellectis SA
CLLS3.570USD
+0.070+2.00%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
258.20MCap. mercado
PérdidaP/E TTM
Más Datos de Cellectis SA Compañía
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.
Información de Cellectis SA
Símbolo de cotizaciónCLLS
Nombre de la empresaCellectis SA
Fecha de salida a bolsaFeb 06, 2007
Director ejecutivoSourdive (David J.D)
Número de empleados224
Tipo de seguridadDepository Receipt
Fin del año fiscalFeb 06
Dirección8, rue de la Croix Jarry
CiudadPARIS
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísFrance
Código postal75013
Teléfono33181691600
Sitio Webhttps://www.cellectis.com/
Símbolo de cotizaciónCLLS
Fecha de salida a bolsaFeb 06, 2007
Director ejecutivoSourdive (David J.D)
Ejecutivos de Cellectis SA
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Andre Choulika, Ph.D.
Dr. Andre Choulika, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
--
--
Dr. David Sourdive, Ph.D.
Dr. David Sourdive, Ph.D.
Deputy Chief Executive Officer, Co-Founder, Executive Vice President - CMC and Manufacturing, Director
Deputy Chief Executive Officer, Co-Founder, Executive Vice President - CMC and Manufacturing, Director
--
--
Dr. Philippe Duchateau, Ph.D.
Dr. Philippe Duchateau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Pierre Bastid
Mr. Pierre Bastid
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Laurent Arthaud
Mr. Laurent Arthaud
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Rainer J. Boehm, M.D.
Dr. Rainer J. Boehm, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Stephan Reynier
Mr. Stephan Reynier
Chief Regulatory and Pharmaceutical Compliance Officer
Chief Regulatory and Pharmaceutical Compliance Officer
--
--
Ms. Marie-Bleuenn Terrier
Ms. Marie-Bleuenn Terrier
General Counsel
General Counsel
--
--
Mr. Arthur Stril
Mr. Arthur Stril
Chief Financial Officer and Chief Business Officer
Chief Financial Officer and Chief Business Officer
--
--
Dr. Steven (Steve) Doares, Ph.D.
Dr. Steven (Steve) Doares, Ph.D.
Senior Vice President - US Manufacturing
Senior Vice President - US Manufacturing
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Andre Choulika, Ph.D.
Dr. Andre Choulika, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
--
--
Dr. David Sourdive, Ph.D.
Dr. David Sourdive, Ph.D.
Deputy Chief Executive Officer, Co-Founder, Executive Vice President - CMC and Manufacturing, Director
Deputy Chief Executive Officer, Co-Founder, Executive Vice President - CMC and Manufacturing, Director
--
--
Dr. Philippe Duchateau, Ph.D.
Dr. Philippe Duchateau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Pierre Bastid
Mr. Pierre Bastid
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Laurent Arthaud
Mr. Laurent Arthaud
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Rainer J. Boehm, M.D.
Dr. Rainer J. Boehm, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Desglose de ingresos
Divisa: USDActualizado: mar., 6 de ene
Divisa: USDActualizado: mar., 6 de ene
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
La empresa aún no ha revelado los datos relevantes.
Por regiónUSD
Nombre
Ganancia
Proporción
France
41.51M
0.00%
Other
0.00
0.00%
USA
0.00
0.00%
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: dom., 4 de ene
Actualizado: dom., 4 de ene
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Long Focus Capital Management LLC
5.70%
B Group, Inc.
4.54%
UBS Asset Management Switzerland AG
1.99%
BlackRock Institutional Trust Company, N.A.
0.48%
Nomura Investment Management Business Trust
0.31%
Otro
86.98%
Accionistas
Accionistas
Proporción
Long Focus Capital Management LLC
5.70%
B Group, Inc.
4.54%
UBS Asset Management Switzerland AG
1.99%
BlackRock Institutional Trust Company, N.A.
0.48%
Nomura Investment Management Business Trust
0.31%
Otro
86.98%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
7.72%
Hedge Fund
6.09%
Investment Advisor/Hedge Fund
0.42%
Research Firm
0.22%
Otro
85.55%
Participación institucional
Actualizado: lun., 8 de dic
Actualizado: lun., 8 de dic
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
70
10.10M
29.55%
--
2025Q3
77
10.10M
29.65%
-3.45M
2025Q2
79
13.55M
35.05%
-1.95M
2025Q1
82
15.50M
31.47%
-7.25M
2024Q4
86
16.67M
24.79%
+2.93M
2024Q3
104
15.35M
28.39%
+1.55M
2024Q2
103
13.80M
26.34%
-48.27K
2024Q1
112
13.82M
26.53%
-5.23M
2023Q4
124
13.74M
31.43%
+147.34K
2023Q3
142
13.59M
44.11%
-2.54M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Long Focus Capital Management LLC
4.12M
5.7%
-594.03K
-12.59%
Sep 30, 2025
B Group, Inc.
3.28M
4.54%
+25.00K
+0.77%
Sep 30, 2025
UBS Asset Management Switzerland AG
1.44M
1.99%
--
--
Jan 31, 2025
BlackRock Institutional Trust Company, N.A.
337.45K
0.47%
+337.45K
--
Dec 31, 2025
Nomura Investment Management Business Trust
226.88K
0.31%
--
--
Sep 30, 2025
Bellecapital AG
226.07K
0.31%
--
--
Jun 30, 2025
Citadel Advisors LLC
221.96K
0.31%
+221.96K
--
Sep 30, 2025
LPL Financial LLC
85.15K
0.12%
-515.00
-0.60%
Sep 30, 2025
Morgan Stanley & Co. International Plc
83.39K
0.12%
+10.20K
+13.94%
Sep 30, 2025
Millennium Management LLC
57.74K
0.08%
+22.08K
+61.92%
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
ActivePassive International Equity ETF
0%
Avantis International Equity ETF
0%
ActivePassive International Equity ETF
Proporción0%
Avantis International Equity ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
